學習2023年版慢性阻塞性肺疾病全球創議的若干體會_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 何權瀛

北京大學人民醫院呼吸科（北京 100083）;

Corresponding?author：

何權瀛, Email: hxk313@126.com

Keywords：

DOI：

10.7507/1671-6205.202212063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 何權瀛. 學習2023年版慢性阻塞性肺疾病全球創議的若干體會. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(12): 837-841. doi: 10.7507/1671-6205.202212063 Copy

1.	Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2023 Report [EB/OL]. https://goldcopd.org/2023-gold-report-2/.
2.	趙寧寧, 周玉明. 保留比值受損肺功能人群研究進展. 中華結核和呼吸雜志, 2022, 45(10): 1046-1050.
3.	Wan ES, Castaldi PJ, Cho MH, et al. COPDGene Investigators. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res, 2014, 15(1): 89.
4.	Wan ES, Hokanson JE, Regan EA, et al. Significant spirometric transitions and preserved ratio impaired spirometry among ever smokers. Chest, 2022, 161(3): 651-661.
5.	Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J, 2020, 55(1): 1901217.
6.	Wan ES, Fortis S, Regan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med, 2018, 198(11): 1397-1405.
7.	Keener A. Redefining the diagnostic criteria for COPD. Nature, 2020, 581(7807): S4-S6.
8.	周德訓, 魏敬安, 陳清, 等. 肺功能非特異性表現的特點與臨床意義. 中華結核和呼吸雜志, 2013, 36(11): 821-824.
9.	崔佳, 許小毛, 張洪勝, 等. 肺通氣功能非特異性表現的分布及特點初探. 中華結核和呼吸雜志, 2016, 39(3): 193-197.
10.	黃永康, 張文宇, 黃建安. 靶肺去神經療法在慢性阻塞性肺疾病中的應用進展. 中國呼吸與危重監護雜志, 2021, 20(11): 821-823.
11.	何權瀛. 對于將切斷迷走神經用于治療慢性阻塞性肺疾病的不同意見. 中國呼吸與危重監護雜志, 2022, 21(7): 457-458.
12.	張夢, 魏智民, 崔華, 等. 北京地區4960例慢性阻塞性肺疾病住院患者合并卒中情況的多中心臨床調查. 解放軍醫學院學報, 2013, 34(6): 562-565.
13.	全國第五次結核病流行病學抽樣調查技術指導組, 全國第五次結核病流行病學抽樣調查辦公室. 2010年全國第五次結核病流行病學抽樣調查報告. 中國防癆雜志, 2012, 34(8): 485-508.

1. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2023 Report [EB/OL]. https://goldcopd.org/2023-gold-report-2/.
2. 趙寧寧, 周玉明. 保留比值受損肺功能人群研究進展. 中華結核和呼吸雜志, 2022, 45(10): 1046-1050.
3. Wan ES, Castaldi PJ, Cho MH, et al. COPDGene Investigators. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res, 2014, 15(1): 89.
4. Wan ES, Hokanson JE, Regan EA, et al. Significant spirometric transitions and preserved ratio impaired spirometry among ever smokers. Chest, 2022, 161(3): 651-661.
5. Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J, 2020, 55(1): 1901217.
6. Wan ES, Fortis S, Regan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med, 2018, 198(11): 1397-1405.
7. Keener A. Redefining the diagnostic criteria for COPD. Nature, 2020, 581(7807): S4-S6.
8. 周德訓, 魏敬安, 陳清, 等. 肺功能非特異性表現的特點與臨床意義. 中華結核和呼吸雜志, 2013, 36(11): 821-824.
9. 崔佳, 許小毛, 張洪勝, 等. 肺通氣功能非特異性表現的分布及特點初探. 中華結核和呼吸雜志, 2016, 39(3): 193-197.
10. 黃永康, 張文宇, 黃建安. 靶肺去神經療法在慢性阻塞性肺疾病中的應用進展. 中國呼吸與危重監護雜志, 2021, 20(11): 821-823.
11. 何權瀛. 對于將切斷迷走神經用于治療慢性阻塞性肺疾病的不同意見. 中國呼吸與危重監護雜志, 2022, 21(7): 457-458.
12. 張夢, 魏智民, 崔華, 等. 北京地區4960例慢性阻塞性肺疾病住院患者合并卒中情況的多中心臨床調查. 解放軍醫學院學報, 2013, 34(6): 562-565.
13. 全國第五次結核病流行病學抽樣調查技術指導組, 全國第五次結核病流行病學抽樣調查辦公室. 2010年全國第五次結核病流行病學抽樣調查報告. 中國防癆雜志, 2012, 34(8): 485-508.

Next Article
Effect of MCC950 intervention on the expression levels of NLRP3 inflammasome and Muc5ac in airway of asthmatic mice

Chinese Journal of Respiratory and Critical Care Medicine

學習2023年版慢性阻塞性肺疾病全球創議的若干體會

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content